Source: Medicines and Medical Devices Safety Authority (NZ) Revision Year: 2019 Publisher: Novartis New Zealand Limited, 109 Carlton Gore Road, Newmarket, Auckland 1023, PO Box 99102, Newmarket, Auckland 1149, Telephone: 0800 354 335
DYNACIRC SRO 2.5mg Modified Release (SRO) Capsules.
DYNACIRC SRO 5mg Modified Release (SRO) Capsules.
| Pharmaceutical Form |
|---|
|
2.5 mg and 5 mg modified release capsules (SRO capsules) for oral administration. |
One 2.5mg Modified Release (SRO) Capsule contains 2.5 mg of isradipine.
One 5 mg Modified Release (SRO) Capsule contains 5 mg of isradipine.
For the full list of excipients, see Section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Isradipine |
Isradipine is a potent dihydropyridine calcium channel blocker with selective activity on voltage-gated calcium channels (L-type or “long acting”). Isradipine has a higher affinity for such calcium channels in arterial smooth muscle than for those in the myocardium. It thus dilates arterial vascular beds, in particular those of the heart, brain and skeletal muscle without depressing cardiac function. |
| List of Excipients |
|---|
|
Cellulose, microcrystalline |
Alu/PVC/PVDC blister pack containing 10 or 30 capsules.
Not all pack sizes may be marketed.
Novartis New Zealand Limited, 109 Carlton Gore Road, Newmarket, Auckland 1023, PO Box 99102, Newmarket, Auckland 1149, Telephone: 0800 354 335
30 May 1991
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
